September 12, 2016

Mayo Clinic’s Collaboration with iSpecimen® May Bolster Research

By Sharon Rosen

Article by Susan Buckles, Public Affairs

iSpecimen®, a privately held biomedical company, has announced a new collaboration with Mayo Clinic Center for Individualized Medicine to make serum from cancer patients more readily available to scientists. Bringing together patient samples, scientists and biomedical business is an important step toward advancing research into personalized treatments for cancer, Alzheimer’s and many other diseases.

Dr. Stephen Thibodeau

Dr. Stephen Thibodeau

“Breakthrough discoveries would not be possible without the human samples investigators use in their studies,” says Stephen Thibodeau, Ph.D., the David F. and Margaret T. Grohne Director, Biorepositories Program, Mayo Clinic Center for Individualized Medicine. “The demand for high quality annotated human samples for research has been escalating at a rapid pace now that DNA testing is becoming faster and cheaper. This collaboration will make it possible to more easily connect investigators with qualified samples that may lead to strong studies and new therapies.”

Read more about this collaboration in iSpecimen’s news release.

Join us to learn more about precision medicine

Hear experts discuss the latest research in precision medicine and how it can be applied to improve treatments for many conditions at Individualizing Medicine 2016: Advancing Care Through Genomics. The Mayo Clinic Center for Individualized Medicine, is hosting the fifth annual genomics conference, October 5–6, in Rochester, Minn.

The Mayo Clinic Center for Individualized Medicine is hosting the conference with support from the Satter Foundation.

IM Ad Group 1 822x150-2

Tags: #CIMCon16, #Genomics data, #iSpecimen, #PrecisionMedicine, Biospecimens, center for individualized medicine, Dr. Stephen Thibodeau, Genomic Research, mayo clinic, Uncategorized

Contact Us · Privacy Policy